真实世界数据揭示炎症性肠病患者药物不良反应:IBDREAM登记研究
该回顾性多中心研究基于荷兰全国IBDREAM登记,评估了IBD维持治疗药物的不良反应,共纳入1179例患者的3080条不良反应报告。另有7种不良反应累积发生率高于SmPC。结论提示真实世界数据可补充药品安全性信息,助力更新SmPC并改善患者风险沟通。
要点
- 硫唑嘌呤和巯嘌呤相关发热是最常见的新关联。
- 7种不良反应累积发生率高于SmPC,包括巯嘌呤相关关节痛等。
核心结论
- 真实世界数据揭示IBD治疗药物存在新的不良反应关联及更高的累积发生率。
- 这些信息有助于更新SmPC,优化风险沟通与患者用药安全。
研究设计与样本
- 回顾性多中心研究,基于荷兰全国IBDREAM登记。
- 仅纳入与IBD维持治疗药物相关的不良反应报告。
- 共报告3080条不良反应,涉及1179例患者。
- 所有不良反应经医疗专业人员核实并由药物警戒评估员编码。
主要发现
- 最常见的未提及关联为硫唑嘌呤相关发热(3.1%)和巯嘌呤相关发热(4.9%)。
- 7种不良反应的累积发生率高于SmPC,包括巯嘌呤相关关节痛(2.5%)、硫唑嘌呤相关腹泻(1.4%)、脱发(1.2%)和感染(1.6%)。
临床怎么用
- 临床药师应关注IBD治疗药物在真实世界中新发现的不良反应,如发热、关节痛等。
- 在患者用药教育和风险沟通中,可参考本研究结果补充SmPC未涵盖的风险信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Inflammatory bowel disease (IBD) frequently requires chronic immunosuppressive treatment and active involvement from patients during treatment decision making. Information about the risk of developing adverse drug reactions (ADRs) to IBD therapies is required in this process. OBJECTIVE: The aim of this study was to describe the ADRs reported in IBD patients from real-world data, using the Dutch nationwide IBDREAM registry, and compare the occurrence and cumulative incidences with the Summary of Product Characteristics (SmPC) of the associated drugs. METHODS: In this retrospective multicentre study, ADRs related to IBD medication were assessed. Only reports associated with the use of drugs used for the maintenance treatment of IBD were included. All ADRs were verified by healthcare professionals and coded by trained pharmacovigilance assessors. RESULTS: In total, 3080 ADRs were reported in 1179 patients. Twenty-three new drug-ADR associations related to the use of azathioprine, mercaptopurine, infliximab, oral mesalamine and thioguanine were reported in the IBDREAM registry that were not mentioned in the corresponding SmPCs. The most frequently reported new association was pyrexia for azathioprine (3.1%) and mercaptopurine (4.9%). In addition, there were seven ADRs with a higher cumulative incidence in IBDREAM compared with the SmPC, and included, among others, arthralgia during mercaptopurine use (2.5%), and diarrhoea (1.4%), alopecia (1.2%) and infections (1.6%) during azathioprine use. CONCLUSIONS: Based on real-world data, ADR reporting demonstrated new ADRs and higher incidences of ADRs to IBD therapies. This information will contribute to drug safety by updating the SmPCs, allowing better risk assessment and communication towards patients.
引用
- Giraud EL, Thomas PWA, van Lint JA, et al. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. Drug Saf. 2021. PMID: 33538994. doi:10.1007/s40264-021-01045-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。